The Epidermal Growth Factor Receptor in Breast Cancer
The Epidermal Growth Factor Receptor in Breast Cancer
复制标题
DOI：
10.1023/a:1026399613946
复制
发表时间：
1997-04-01
影响因子：
2.5
通讯作者：
Harris, Adrian L.
中科院分区：
文献类型：
--
作者：
Fox, Stephen B.;Harris, Adrian L.
表皮生长因子受体 (EGFR)(3) 是一种由多种配体激活的 170 kD 跨膜酪氨酸激酶。它是正常乳房发育和哺乳所必需的，并且在大约 40% 的乳腺癌中异常表达，特别是那些预后不良表型的乳腺癌。由于许多肿瘤类型中 EGF 受体水平升高，因此正在研究其作为治疗靶点的潜力，利用 EGF 受体靶向毒素以及干扰信号传导和抗受体抗体的药物。当与化疗联合用于辅助情况时，这些方法可能是最有效的。
The epidermal growth factor receptor (EGFR)(3) is a 170 kD transmembrane tyrosine kinase activated by several ligands. It is required for normal mammary development and lactation and is aberrantly expressed in approximately 40% of breast carcinomas, particularly those with a poor prognostic phenotype. Since EGF receptor levels are elevated in a high proportion of many tumor types its potential as a therapy target is being investigated using the EGF receptor to target toxins, as well as drugs that interfere with signaling and anti-receptor antibodies. These approaches are likely to be most effective when used in the adjuvant situation in combination with chemotherapy.